Topical Lidocaine Has Super Potency and Should Be Discarded


Company Announcement Date:
December 07, 2021
FDA Publish Date:
December 07, 2021
Product Type:
Reason for Announcement:
Super potent
Company Name:
Teligent Pharma, Inc.
Brand Name:
Teligent Pharma, Inc.
Product Description:
Lidocaine HCl Topical Solution USP 4%, 50ml

Company Announcement

FOR IMMEDIATE RELEASE –07 December 2021 – Buena, NJ, Teligent Pharma, Inc. is voluntarily recalling two lots of Lidocaine HCl Topical Solution USP 4%, 50ml in a screw cap glass bottle listed in the table below to the user level. The product is being recalled because the firms testing has found it to be super potent based on an Out of Specification (OOS) result obtained at the 9-month (Lot 16345) and 18-month (Lot 15594) stability timepoint.

Risk Statement: Use of the super potent product would result in a higher than intended lidocaine dose above that intended. An increased lidocaine dose could lead to the development of local anesthetic systemic toxicity depending on the duration of the treatment and the specific patient. Local anesthetic systemic toxicity can result in central nervous system reactions including excitation and/or depression and more serious signs of cardiovascular toxicity, such as bradycardia, hypotension, and even cardiovascular collapse can present very quickly. If local anesthetic systemic toxicity is not recognized and treated quickly, severe morbidity and even death can result. Adults and the elderly who are more likely to use this product as well as children of lower body weight are more likely to experience local anesthetic systemic toxicity if a higher than intended lidocaine concentration is administered. To date, Teligent Pharma, Inc. has not received any reports of adverse events related to this recall.

Product NDC Lot Number Expiration
Lidocaine Hydrochloride Topical Solution
USP 4% (40 mg/mL), 50mL bottle
63739-997-64 15594 05/2023
63739-997-64 16345 01/2024

The product is indicated for the production of topical anesthesia of accessible mucous membranes of the oral and nasal cavities and proximal portions of the digestive tract and is packaged in a 50ml glass bottle with a screw cap with the identification NDC 63739-997-64. The product can be identified by the following labeling: Lidocaine Hydrochloride Topical Solution USP 4% (40 mg/mL). Product was distributed at the wholesale and retail distribution levels nationwide in the US.

Teligent Pharma, Inc. is notifying its distributors via Fed-Ex and is arranging for return of all recalled products. Consumers, distributors, and retailers that have product which is being recalled should stop using or distributing and return to place of purchase.

Consumers and patients that have Lidocaine HCl Topical Solution 4% which is being recalled are asked to discontinue use and call 1-856.697.1441 press * to reach the medical information call center Monday through Friday, 8am – 5pm or send an e-mail to [email protected] for any product questions and to receive instructions on reimbursement and shipping info for Lot #15594 Exp. 05/2023 and Lot #16345 Exp. 01/2024.

Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Read the full report here.

As published on